Article Text
PDF
Statistics from Altmetric.com
‘The people of this country have had enough of experts…’
This extraordinary quotation is from a British politician who most definitely is not a neurologist, and certainly not a reader of Practical Neurology. Readers of this journal love experts, and particularly those who think critically about what they do, and can distil their knowledge so that we, the jobbing neurologists, can make this expertise available to our patients. Experts are sometimes characterised (unfairly) as knowing a lot about a little, about those rare diseases that we rarely see in the clinic.
Dementia is very common and all too often the diagnosis is relatively straightforward, particularly for more established disease. But having made the diagnosis what should we do next? Tony Bayer shares his expertise in the management of patients with dementia and highlights a range of simple and low-tech interventions that can help both the patient with dementia and their family (page 296).
Stroke …
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
- Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
- Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
- Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
- Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells